# US Predictive Genetic Testing and Consumer Wellness Genomics Market

> US Genomics Market Research Report By Application (Drug Discovery, Clinical Diagnostics, Personalized Medicine, Genetic Testing), By Technology (Sequencing, Microarray, PCR, CRISPR) and By End Use (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies) - Growth & Industry Forecast 2025 To 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.9%
- **2024:** $ 1,302.01 Million
- **2025:** $ 1,417.89 Million
- **2035:** $ 3,327.05 Million
- **Key Players:** 23andMe (US), Ancestry (US), MyHeritage (IL), Invitae (US), Color Genomics (US), Gene by Gene (US), Fulgent Genetics (US), GenoPalate (US)

**Report ID:** MRFR/LS/18153-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-predictive-genetic-testing-and-consumer-wellness-genomics-market-19700

---

## Market Summary

## **US Genomics Market Overview**

As per MRFR analysis, the US Genomics Market Size was estimated at 12.09 (USD Billion) in 2023. The US Genomics Market Industry is expected to grow from 13.5(USD Billion) in 2024 to 32.4 (USD Billion) by 2035. The US Genomics Market CAGR (growth rate) is expected to be around 8.284% during the forecast period (2025 - 2035).

### **Key US Genomics Market Trends Highlighted**

The US Genomics Market is currently experiencing several noteworthy trends that are shaping its landscape. There is a significant increase in the demand for personalized medicine, driven by advancements in genomic research and technology. Patients are increasingly seeking treatments that are tailored to their genetic profiles, which has led to a greater focus on precision medicine initiatives. Furthermore, the integration of genomics into clinical practices is supported by government backing and funding, aimed at enhancing healthcare outcomes. This strong support creates a conducive environment for growth.

Key market drivers include the rising prevalence of genetic disorders and chronic diseases, which further fuels the need for genomic solutions.Additionally, advancements in technologies such as CRISPR and next-generation sequencing are enhancing capabilities for genetic testing and research, attracting investments and interest in the genomics field. Opportunities to be explored encompass the development of cost-effective genomic tools and services, allowing smaller healthcare facilities and laboratories to participate in genetic testing. The clear regulatory pathways established by the FDA for genomic products also create favorable conditions for market players to innovate and bring their solutions to the forefront.

Trends in recent times reflect a surge in the collaboration between biotechnology companies and academic institutions, facilitating knowledge sharing and accelerating research and development.As a result, we observe a growing emphasis on the ethical implications of genomics, spurring discussions about data privacy and equity in access to genomic services. In summary, the US Genomics Market is vibrant with growth potential, influenced by advancements in technology, supportive policies, and evolving consumer expectations in the healthcare sector.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Genomics Market Drivers**

### **Rising Demand for Personalized Medicine**

The US[Genomics Market](../../../reports/genomics-market-12283) Industry is experiencing substantial growth due to an increasing demand for personalized medicine. According to the National Institutes of Health (NIH), personalized medicine can significantly improve the effectiveness of treatment outcomes for various diseases, with estimates suggesting that targeted therapies could improve cancer treatment efficiency by nearly 25% in the coming years. Companies like Illumina, a leading genomic technology provider, have advanced technologies that facilitate the sequencing of genomes for individualized treatment plans, further fueling this demand.

The National Cancer Institute reported that about 1.9 million new cancer cases are expected to be diagnosed in 2021 alone, enhancing the need for personalized genomic solutions tailored to these patients. The growing interest from healthcare providers and patients towards personalized healthcare approaches is a significant driver for the US Genomics Market and is expected to lead to increased market size and value from the current levels through innovative use of genomic data.

### **Advancements in Genome Sequencing Technologies**

Technological advancements in genome sequencing are another crucial driver of the US Genomics Market Industry. Over the past decade, the cost of genome sequencing has dropped dramatically, with estimates showing that costs have plummeted from around 100 million USD in the early 2000s to under 1,000 USD today. The introduction of next-generation sequencing (NGS) platforms has revolutionized genomic studies and diagnostics, allowing for faster and more accurate analysis.

Organizations like Thermo Fisher Scientific have introduced state-of-the-art NGS instruments that cater to various sectors, improving accessibility to genomic solutions across the US. As a result, the rate of genomic data generation is leading to a rapid expansion of genetic research and diagnostics, further stimulating growth in the US Genomics Market.

### **Growing Focus on Genomic Research and Development**

Research and Development (R&D) in the genomics sector is a significant growth driver for the US Genomics Market Industry. The US government has made substantial investments in genomics initiatives, with the National Human Genome Research Institute allocating more than 500 million USD annually towards the advancement of genomic research. This funding not only encourages innovations in genetic studies but also draws academic institutions and biotechnology firms into the sphere of biosciences, thereby expanding the market.

Partnerships between leading organizations such as Genentech and academic institutions support ongoing R&D efforts, highlighting the collaborative approach to driving genomic advancements. As the US continues to prioritize genomic research, the market is projected to grow in proportion to these rising investments and the subsequent innovations that are developed as a result.

## **US Genomics Market Segment Insights**

### **Genomics Market Application Insights**

The Application segment of the US Genomics Market plays a pivotal role in the overall development and utilization of genomic technologies, significantly driving advancements across various healthcare and biotechnological fields. This segment encompasses crucial areas such as Drug Discovery, Clinical Diagnostics, Personalized Medicine, and Genetic Testing, all of which are integral in enhancing patient outcomes and streamlining processes within the healthcare system. Drug Discovery is especially vital as it leverages genomic data to identify novel therapeutic targets, dramatically improving the efficiency of developing new medications.

Clinical Diagnostics, on the other hand, integrates genomic insights for accurate disease diagnosis, enabling healthcare practitioners to provide timely and appropriate treatments based on an individual’s genetic makeup. Personalized Medicine epitomizes the shift toward more tailored healthcare solutions, where treatments and preventive strategies are customized to fit the unique genetic profiles of patients, reflecting a significant evolution in healthcare practices in the US. Genetic Testing remains a cornerstone, empowering both individuals and healthcare providers with crucial information related to hereditary conditions, risk factors, and potential health challenges, which has transformed the preventative aspect of medicine.

Overall, the Application segment encapsulates the innovative uses of genomics, demonstrating significant market growth driven by increasing demand for precision medicine, evolving regulatory landscapes, and heightened awareness about genetics among consumers and professionals alike. The convergence of technological advancements with genomic tools has positioned this segment as a leader in reshaping the future of healthcare in the US, with promising implications for improving treatment outcomes and optimizing drug efficacy.

The focus on a genome-centric approach highlights the strategic importance of the Application segment in addressing complex healthcare challenges, contributing substantially to the broader US Genomics Market statistics and maintaining its relevance in the ongoing global health conversation.

This segment continues to present opportunities for innovation and investment, promising a transformative impact on public health and the biopharmaceutical industry, while also addressing societal needs for more effective, accountable, and equitable healthcare solutions. As the US continues to harness the potential of genomics, data-driven decisions in this domain are likely to pave the way for continued growth and enhanced quality of care across the board.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Genomics Market Technology Insights**

The Technology segment within the US Genomics Market showcases a robust landscape focused on advanced techniques and methodologies that drive innovation in genetics. Key areas include Sequencing, which has revolutionized genetic analysis by enabling rapid and affordable genome mapping, thus supporting developments in personalized medicine. Microarray technology plays a crucial role in simultaneously analyzing thousands of genes, facilitating advancements in diagnostics and drug discovery. PCR, or Polymerase Chain Reaction, remains essential for amplifying specific DNA segments, significantly impacting Research and Development activities across various applications, including infectious disease testing and genetic research.

Meanwhile, CRISPR technology is at the forefront of gene editing, offering unprecedented precision and versatility, with applications ranging from agriculture to therapeutic interventions. The interplay of these technologies is spurred by growing demand for genetic insights in healthcare, the agricultural sector, and environmental sciences, reflecting a strong trend towards precision medicine and targeted treatments.

As the US continues to invest in genomic initiatives, the opportunities fostered by these technologies underline their pivotal role in the ongoing evolution of the genomics industry.Overall, the US Genomics Market is poised for substantial growth, driven by these technological advancements and their widespread applications in improving health outcomes and enhancing scientific research.

### **Genomics Market End Use Insights**

The US Genomics Market encompasses a dynamic landscape shaped significantly by its End Use applications. Hospitals represent a crucial component, harnessing genomics for personalized medicine and enhancing patient care through genetic testing. Likewise, Diagnostic Laboratories play a pivotal role in identifying genetic disorders, driving demand for advanced genomic solutions. Research Institutes contribute substantially by facilitating groundbreaking studies and advancements in genomics, ultimately contributing to a deeper understanding of complex diseases.

Additionally, Pharmaceutical Companies leverage genomic data to propel drug discovery, streamline clinical trials, and develop targeted therapies, highlighting the strategic importance of genomic insights in modern healthcare. Together, these sectors form a robust ecosystem that not only advances medical research but also supports efficient healthcare delivery, reflecting the continuous evolution and growth potential within the US Genomics Market. The increasing reliance on genomic technologies across these areas underscores the essential nature of this market segment and the opportunities it presents for innovation and development in healthcare solutions.

## **US Genomics Market Key Players and Competitive Insights**

The US Genomics Market is characterized by intense competition among major players striving for innovation and market share. With advances in technology and an increasing focus on personalized medicine, companies are heavily investing in research and development to enhance their product offerings. The market is primarily driven by rising demand for genetic testing, genomic sequencing, and molecular diagnostics, as healthcare continues to evolve towards a more tailored approach. As a result, strategic initiatives such as partnerships, collaborations, mergers, and acquisitions play a crucial role in positioning companies for future growth and maintaining competitive advantages in this rapidly changing landscape.

Illumina holds a leading position within the US Genomics Market due to its pioneering technologies in next-generation sequencing (NGS) and comprehensive genomics solutions. The company's innovative platforms and extensive product portfolio enable researchers and clinicians to perform sophisticated genetic analyses quickly and accurately. Illumina has established a robust market presence through continuous advancements in its sequencing technology, driving applications across various sectors such as oncology, reproductive health, and genetic disease study. The firm's focus on enhancing its high throughput sequencing capabilities, alongside its commitment to making sequencing accessible and affordable, strengthens its leadership in the market.

Furthermore, Illumina consistently engages in strategic collaborations and partnerships, positioning itself effectively to capitalize on emerging opportunities and trends in genomics.

Exact Sciences has made significant strides in the US Genomics Market, particularly through its expertise in the field of cancer diagnostics. The company is primarily known for its non-invasive testing solutions, with flagship products that cater to early cancer detection, notably colorectal cancer screening tests. Exact Sciences’ strong presence in the market is bolstered by its commitment to innovation, with ongoing research and development efforts aimed at expanding its product offerings and enhancing test accuracy.

The company has successfully pursued strategic mergers and acquisitions to strengthen its capabilities and access new technologies, resulting in an expanded portfolio and increased market reach. Exact Sciences is recognized for its emphasis on delivering healthcare solutions that improve patient outcomes, which further solidifies its position in the competitive landscape of the US Genomics Market.

### **Key Companies in the US Genomics Market Include**

## **US Genomics Market Industry Developments**

Recent developments in the US Genomics Market reflect significant advancements and strategic movements among key players. Illumina announced in August 2023 its collaboration with a leading pharmaceutical company to enhance genomic sequencing technology for personalized medicine. Exact Sciences has been actively increasing its market share through targeted acquisitions aimed at expanding its cancer detection capabilities, with recent investments in innovative technologies. Bristol Myers Squibb continues to focus on precision medicine, enhancing its genomic research collaboration efforts, especially looking to improve cancer therapies.

In terms of mergers and acquisitions, Thermo Fisher Scientific completed the acquisition of PPD in June 2021, significantly expanding its capabilities in genomic and laboratory services. BioRad Laboratories has also engaged in partnerships to leverage advancements in proteomics linked to genomics applications. The US genomics market has seen notable growth, with estimates suggesting a market valuation exceeding USD 25 billion in 2023, driven largely by technological innovations and increasing demand for genomic sequencing in healthcare.

Companies like Roche and Guardant Health are continuously evolving to meet the rising need for genomic data, particularly amidst the ongoing push toward personalized medicine strategies in the US healthcare landscape.

## **US Genomics Market Segmentation Insights**

### **Genomics Market Application Outlook**

### **Genomics Market Technology Outlook**

### **Genomics Market End Use Outlook**

## Market Drivers

### Rising Health Awareness

The increasing awareness of health and wellness among consumers appears to be a significant driver for the predictive genetic-testing-and-consumer-wellness-genomics market. As individuals become more informed about the importance of preventive healthcare, they are more likely to seek genetic testing services. This trend is reflected in a survey indicating that approximately 70% of consumers in the US are interested in understanding their genetic predispositions to various health conditions. Consequently, this heightened awareness is likely to propel demand for genetic testing services, as consumers aim to make informed lifestyle choices based on their genetic profiles.

### Integration of AI and Machine Learning

The integration of artificial intelligence (AI) and machine learning technologies into the predictive genetic-testing-and-consumer-wellness-genomics market is transforming how genetic data is analyzed and interpreted. These technologies enable more accurate predictions of health risks and personalized wellness recommendations. For instance, AI algorithms can process vast amounts of genetic data, identifying patterns that may not be apparent through traditional analysis. This capability is expected to enhance the accuracy of genetic tests, potentially increasing market growth by an estimated 25% over the next five years as consumers seek more reliable insights into their health.

### Expansion of Direct-to-Consumer Testing

The expansion of direct-to-consumer (DTC) genetic testing services is reshaping the landscape of the predictive genetic-testing-and-consumer-wellness-genomics market. Consumers now have greater access to genetic testing without the need for a healthcare provider's referral. This trend is evidenced by a report indicating that the DTC genetic testing market is expected to grow by 15% annually. As more companies enter the market, offering a variety of tests, consumers are likely to embrace these services, driving overall market growth and increasing awareness of genetic health.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is a crucial driver for the predictive genetic-testing-and-consumer-wellness-genomics market. As healthcare moves away from a one-size-fits-all approach, there is a growing recognition of the need for tailored treatment plans based on individual genetic profiles. This trend is supported by research indicating that personalized medicine can improve treatment efficacy by up to 30%. As healthcare providers increasingly adopt genetic testing to inform treatment decisions, the demand for these services is likely to rise, further propelling the market's expansion.

### Increased Investment in Genomic Research

The surge in investment in genomic research is significantly impacting the predictive genetic-testing-and-consumer-wellness-genomics market. Government and private sector funding for genomic studies has increased, leading to advancements in genetic testing technologies and methodologies. In 2025, funding for genomic research in the US is projected to exceed $10 billion, fostering innovation and enhancing the availability of genetic testing services. This influx of capital is likely to accelerate the development of new tests and applications, thereby expanding the market and making genetic testing more accessible to consumers.

## Future Outlook

The [Predictive Genetic Testing and Consumer Wellness Genomics Market](https://www.marketresearchfuture.com/reports/predictive-genetic-testing-and-consumer-wellness-genomics-market-10844) is projected to grow at an 8.9% CAGR from 2025 to 2035, driven by technological advancements and increasing consumer awareness.

**New opportunities:**

- Development of personalized wellness plans based on genetic insights.
- Expansion of direct-to-consumer genetic testing services.
- Integration of AI for enhanced data analysis and consumer engagement.

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Test Type: Predictive Testing (Largest) vs. Consumer Genomics (Fastest-Growing)

In the US predictive genetic-testing-and-consumer-wellness-genomics market, the market share distribution showcases that predictive testing holds a dominant position over the other segment values, making up a significant portion of overall transactions. Meanwhile, consumer genomics has been steadily capturing attention and expanding its foothold, driven by an increasing interest in personalized health and lifestyle choices, which translates into a growing share of the market.

The growth trends indicate a robust trajectory for both predictive testing and consumer genomics. As awareness of genetic factors influencing health continues to rise, predictive testing remains the largest segment. However, consumer genomics is fast becoming the fastest-growing category, fueled by advancements in technology, a decline in testing costs, and an increasing consumer desire for insights into lifestyle and wellness options. This dynamic landscape sets the stage for a compelling competitive environment.

Predictive Testing (Dominant) vs. Wellness Genomics (Emerging)

Predictive testing is characterized by its focus on identifying potential genetic predispositions to various health conditions, making it the dominant force in the market. This segment benefits from widespread acceptance within the healthcare community, as well as consumer trust in its efficacy. As research and evidence accumulate, predictive testing validates its utility in preventive healthcare strategies. Conversely, wellness genomics is an emerging segment that emphasizes lifestyle and wellness optimization based on individual genetic profiles. While not as established as predictive testing, it is gaining traction among health-conscious consumers seeking to enhance their quality of life through personalized approaches. This segment's growth is driven by a burgeoning interest in holistic health and preventive measures, representing a significant shift towards health empowerment.

### By Application: Breast & Ovarian Cancer (Largest) vs. Cardiovascular Screening (Fastest-Growing)

In the US predictive genetic-testing-and-consumer-wellness-genomics market, Breast & Ovarian Cancer testing commands the largest share, driven by increasing awareness and early detection campaigns. Following closely are other applications like Cardiovascular Screening and Diabetic Screening & Monitoring, reflecting a diverse demand spectrum for genetic insights across health concerns.

The growth dynamics of the segment are significantly influenced by advancements in genomic technologies and rising public interest in preventive healthcare. Cardiovascular Screening is particularly notable for its rapidly expanding market presence, propelled by heightened awareness of heart diseases. Additionally, as personalized medicine becomes more mainstream, the application of genetic testing in various diseases, including Colon Cancer and Alzheimer’s, is expected to accelerate significantly in the coming years.

Breast & Ovarian Cancer (Dominant) vs. Cardiovascular Screening (Emerging)

Breast & Ovarian Cancer genetic testing holds a dominant position in the market due to its extensive adoption and the vital role it plays in risk assessment and prevention strategies. The comprehensive nature of this testing empowers individuals with actionable insights, supporting proactive health decisions. In contrast, Cardiovascular Screening represents an emerging frontier, gaining traction as innovations in technology enhance its accuracy and accessibility. With lifestyle-related cardiovascular diseases on the rise, there is a compelling need for genetic screening to guide preventive measures, further expanding the market's horizons. Both segments exemplify the shift towards personalized wellness solutions, catering to diverse patient needs and preferences.

### By Setting Type: Genomic Testing (Largest) vs. Proteomic Testing (Fastest-Growing)

In the US predictive genetic-testing-and-consumer-wellness-genomics market, genomic testing holds a significant market share, dominating the setting type segment. This is driven by the increasing consumer awareness of genetic predispositions and the growing popularity of personalized health insights. Proteomic testing, while smaller in share, is rapidly gaining traction due to advancements in biomarker discovery and its potential to provide comprehensive health assessments, which attract a growing customer base looking for in-depth analysis of their health profile.

Growth trends indicate that the demand for genomic testing is bolstered by advancements in technology, enhanced accuracy, and its role in preventive healthcare. Conversely, proteomic testing is experiencing remarkable growth as it benefits from innovations in technology and the increasing recognition of proteomics in personalized medicine. These trends highlight a shifting focus towards more detailed and individualized approaches to health management, reflecting changing consumer preferences in the industry.

Genomic Testing (Dominant) vs. Proteomic Testing (Emerging)

Genomic testing is characterized by its comprehensive nature, analyzing an individual's DNA to predict health risks and inform personalized treatment options. This segment has become a dominant force in the market due to the extensive research backing its efficacy and the rise in consumer interest in genetic information. In contrast, proteomic testing is emerging as a vital player, focusing on protein analysis and its implications for health. While genomic testing remains more prominent, proteomic testing is rapidly evolving, supported by technological innovations that enhance its accuracy and reliance in clinical settings. Together, they represent a holistic approach to health management, catering to diverse consumer needs in the US predictive genetic-testing-and-consumer-wellness-genomics market.

## Competitive Benchmarking

The predictive genetic-testing-and-consumer-wellness-genomics market is characterized by a dynamic competitive landscape, driven by technological advancements and increasing consumer awareness regarding health and wellness. Key players such as 23andMe (US), Ancestry (US), and Invitae (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. 23andMe (US) focuses on innovation through its direct-to-consumer model, emphasizing user-friendly genetic testing kits that provide insights into health predispositions and ancestry. Ancestry (US), on the other hand, leverages its extensive database to offer personalized ancestry reports, while also expanding its health-related genetic testing services. Invitae (US) positions itself as a leader in clinical genetic testing, emphasizing partnerships with healthcare providers to integrate genetic insights into patient care, thereby shaping a competitive environment that prioritizes personalized health solutions.The market structure appears moderately fragmented, with a mix of established players and emerging startups. Companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. This trend is particularly evident as firms seek to respond swiftly to consumer demands and regulatory changes. The collective influence of these key players fosters a competitive atmosphere where innovation and operational efficiency are paramount.

In October  23andMe (US) announced a strategic partnership with a leading health insurance provider to offer genetic testing as part of preventive health programs. This collaboration is likely to enhance accessibility to genetic testing, potentially increasing consumer adoption and reinforcing 23andMe's position in the market. The integration of genetic insights into health insurance plans may also pave the way for more personalized healthcare solutions, aligning with broader trends in the industry.

In September  Ancestry (US) launched a new feature that combines genetic data with lifestyle and environmental factors to provide users with a more comprehensive health report. This innovation not only differentiates Ancestry from its competitors but also reflects a growing trend towards holistic health assessments. By incorporating lifestyle factors, Ancestry may enhance user engagement and satisfaction, thereby solidifying its market presence.

In August  Invitae (US) expanded its genetic testing portfolio by acquiring a startup specializing in rare disease diagnostics. This acquisition is indicative of Invitae's commitment to broadening its service offerings and enhancing its capabilities in the clinical genetic testing space. By integrating advanced technologies and expertise from the acquired firm, Invitae is likely to strengthen its competitive edge in a rapidly evolving market.

As of November  the competitive trends in the predictive genetic-testing-and-consumer-wellness-genomics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI). Strategic alliances among companies are shaping the landscape, fostering innovation and enhancing service delivery. The shift from price-based competition to a focus on technological advancement and supply chain reliability is evident, suggesting that future competitive differentiation will hinge on the ability to innovate and provide personalized, efficient solutions.

## Recent News & Developments

Recent developments in the US Genomics Market reflect significant advancements and strategic movements among key players. Illumina announced in August 2023 its collaboration with a leading pharmaceutical company to enhance genomic sequencing technology for personalized medicine. Exact Sciences has been actively increasing its market share through targeted acquisitions aimed at expanding its cancer detection capabilities, with recent investments in innovative technologies. Bristol Myers Squibb continues to focus on precision medicine, enhancing its genomic research collaboration efforts, especially looking to improve cancer therapies.

In terms of mergers and acquisitions, Thermo Fisher Scientific completed the acquisition of PPD in June 2021, significantly expanding its capabilities in genomic and laboratory services. BioRad Laboratories has also engaged in partnerships to leverage advancements in proteomics linked to genomics applications. The US genomics market has seen notable growth, with estimates suggesting a market valuation exceeding USD 25 billion in 2023, driven largely by technological innovations and increasing demand for genomic sequencing in healthcare.

Companies like Roche and Guardant Health are continuously evolving to meet the rising need for genomic data, particularly amidst the ongoing push toward personalized medicine strategies in the US healthcare landscape.

## Report Scope

| MARKET SIZE 2024 | 1302.01(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1417.89(USD Million) |
| MARKET SIZE 2035 | 3327.05(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.9% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | 23andMe (US), Ancestry (US), MyHeritage (IL), Invitae (US), Color Genomics (US), Gene by Gene (US), Fulgent Genetics (US), GenoPalate (US) |
| Segments Covered | Test Type, Application, Setting Type |
| Key Market Opportunities | Integration of artificial intelligence in predictive genetic-testing-and-consumer-wellness-genomics market enhances personalized health insights. |
| Key Market Dynamics | Growing consumer demand for personalized health insights drives innovation in predictive genetic testing and wellness genomics. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current market valuation of the US predictive genetic-testing-and-consumer-wellness-genomics market?**
A: The market valuation was $1302.01 Million in 2024.

**Q: What is the projected market size for the US predictive genetic-testing-and-consumer-wellness-genomics market by 2035?**
A: The market is projected to reach $3327.05 Million by 2035.

**Q: What is the expected CAGR for the US predictive genetic-testing-and-consumer-wellness-genomics market during the forecast period 2025 - 2035?**
A: The expected CAGR is 8.9% during the forecast period.

**Q: Which companies are considered key players in the US predictive genetic-testing-and-consumer-wellness-genomics market?**
A: Key players include 23andMe, Ancestry, MyHeritage, Invitae, Color Genomics, Gene by Gene, Fulgent Genetics, and GenoPalate.

**Q: What are the main segments of the US predictive genetic-testing-and-consumer-wellness-genomics market?**
A: The main segments include Predictive Testing, Consumer Genomics, and Wellness Genomics.

**Q: How did the Consumer Genomics segment perform in 2024?**
A: The Consumer Genomics segment was valued at $600.0 Million in 2024.

**Q: What is the valuation range for Predictive Testing in the US market?**
A: The valuation range for Predictive Testing is between $400.0 Million and $1000.0 Million.

**Q: Which application areas are included in the US predictive genetic-testing-and-consumer-wellness-genomics market?**
A: Application areas include Breast & Ovarian Cancer, Cardiovascular Screening, and Diabetic Screening & Monitoring.

**Q: What is the projected valuation for Genomic Testing by 2035?**
A: The projected valuation for Genomic Testing is expected to reach $2027.05 Million by 2035.

**Q: How does the market for Wellness Genomics compare to other segments in 2024?**
A: In 2024, the Wellness Genomics segment was valued at $302.01 Million, indicating a growing interest in health and wellness.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-predictive-genetic-testing-and-consumer-wellness-genomics-market-19700*